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Most of diabetics patients have type 2 diabetes mellitus or non insulin dependent 
diabetes mellitus. Treatment type 2 diabetes mellitus can be done by inhibiting                  
α-glucosidase enzyme which converts carbohydrates into glucose. Sulochrin is one 
of the potential compounds which can inhibit the function of α-glucosidase enzyme. 
This study was carried out to obtain data of sulochrin binding with α-glucosidase 
enzyme as α-glucosidase inhibitor using Radioligand Binding Assay (RBA) method. 
Primary reagent required in RBA method is labeled radioactive ligand (radioligand). 
In this study, the radioligand was sulochrin-125I and prior to sulochrin-125I synthesis, 
the sulochrin-I was synthesized. Sulochrin-I and sulochrin-125I were synthesized and 
their bindings were studied using Radioligand Binding Assay method. Sulochrin-I 
was synthesized with molecular formula C17H15O7I and molecular weight 457.9940. 
Sulochrin-125I was synthesized from sulochrin-I by isotope exchange method. From 
the RBA method, dissociation constant (Kd) and maximum binding (Bmax) were 
obtained 26.316 nM and Bmax 9.302 nM respectively. This low Kd indicated that 
sulochrin was can bind to α-glucosidase.  
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INTRODUCTION 
 
Diabetes mellitus is a chronic disease related 
to insulin resistance. In 2010, people with diabetes 
reached 220 million and in 2025, its estimated 
reaching to 300 million people [1]. Based on IDF 
(International Diabetes Federation) data, Indonesia 
is the fourth largest country for prevalence of 
diabetes [2]. About 90% of diabetics are from type 2 
diabetes mellitus (non insulin-dependent diabetes 
mellitus). Type 2 diabetes mellitus is characterized 
by the occurrence of postprandial hyperglycemia 
[3]. The control of postprandial hyperglycemia is an 
important step for the treatment of diabetes.                    
This can be done by inhibiting the absorption of 
glucose through the inhibition of the carbohydrates 
hydrolyzed enzyme such as α-glucosidase and                    
α-amylase [4]. The α - glucosidase is an enzyme that 
converts carbohydrates into glucose [5,6].                        
The mechanism of action α-glucosidase inhibitors   
                                                 
 Corresponding author. 
   E-mail address: wening@batan.go.id 
is a reversible inhibition, competitive with                          
α-amylase and pancreatic digestive enzymes                       
in the small intestine such as isomaltase,                     
sucrase and maltase. These enzymes play a                      
role in the hydrolyzing of carbohydrates into 
glucose and other monosaccharide. Inhibition of 
these enzymes can inhibit the absorption of glucose 
thereby reducing the state hyperglycemia after                     
meal [6,7]. 
Recently, α-glucosidase inhibitors have                   
been studied, in silico,as well as both in vivo and                 
in vitro. Isolation α-glucosidase inhibitor has                            
widely been done, such as, isolation acarbose                   
from Actinoplanes uthanesis [3,4], isolation                    
vasicine and vasicinol from Adhatoda vasica [8]. 
Voglibose, miglitol were also known as                               
α-glucosidase inhibitor and they were used in                         
type 2 diabetes therapy [9]. Sulochrin                             
(methyl 2-(2,6-dihydroxy-4-methylbenzoyl)-5-
hydroxy-3-methoxybenzoate) isolated from 
Aspegillus terreus, showed its potency as an                       
α-glucosidase inhibitor with IC50 value  8.5 g/mL 
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[10]. Sulochrin derivates, the methyl-4-hydroxy-
5,7-diiodo-6-methoxy-6-methyl-3,4-dioxospiro 
[benzofuran-2(3H), 1-[2,5] cyclohexadiene]-2-
carboxylate and methyl 5,7 dibromo-4-hydroxy-6-
methoxy-6-methyl-3,4dioxospiro[benzofuran-
2(3H), 1-[2,5] cyclohexdiene-2-carboxylate 
showed their glucose uptake activity in rat 
adiposite [11]. In silico field, α-glucosidase 
inhibitor interacted with α-glucosidase residues 
through formation of hydrogen bond. Derivates of 
sulfonamide interacted with Asp349, His348, 
Phe157, Tyr71, Phe177, Arg212 in α-glucosidase 
residues from Saccharomyces cerevisiae [5]. 
Derivatives of salacinol were also known as                     
α-glucosidase inhibitors through interaction with 
Asp327, His600, Asp542, Asp203, Arg526 in 
NtMGAM residues [12].   
In this study, a derivate of sulochrin was 
synthesized and its binding affinity was studied 
using Radioligand Binding Assay (RBA) method. 
The RBA is a method which can be used to 
determine binding affinity of antibodies or receptors 
with ligand using a radioactive as tracer [13]. 
Radioligand (L*)  is reacted with receptor (R) and 
reach equilibrium to get radioligand receptor 
complex (L*R). 
 
 
L* + R         L*R 
 
Purification of  radioligand receptor complex (L*R) 
from unreacted ligand (L*) can be done by  
filtration, centrifugation, dialysis, size exclusion 
chromatography [14]. This purified complex can be 
counted their radioactivity, and from this data, Kd 
and Bmax values will be known. Kd is dissociation 
constant and Bmax is maximum binding that can be 
occurred between ligand and receptor. The RBA 
method needs a ligand compoud labeled with 
radioactive element such as iodine-125 (I-125). The 
radioisotope I-125 is widely used due to its  physical 
half life (59.4 days, long enough for in vitro 
treatment) and its low energy gamma radiation 
(about 25 keV, small enough for being save for 
user) [15]. 
 
 
EXPERIMENTAL METHODS 
 
The materials used were sulochrin (was 
received from Research Center for Chemistry LIPI), 
N,N-dimethylformamide, potassium iodide, iodine, 
sodium  acetate, sodium hydrogen sulfate, sodium 
sulfate anhydrate, methanol, chloroform (Merck), 
Iodine-125 as Na
125
I (PRR-BATAN), α-glucosidase 
enzyme from Shaccharomyces sp (Wako Pure 
Chemistry Industry), bovine serum albumin, 
polyethylene glycol (Sigma-Aldrich). The 
equipments used were gamma counter (Nucleus), 
micropipette (Eppendorf), magnetic stirrer, 
analytical balance (Sartorius). 
 
 
Synthesis of sulochrin-I [11] 
 
Procedure of synthesis sulochrin-I was 
performed in similar manner to procedure reported 
previously [11]. Sulochrin (4 mg, 12 µmol)         
was dissolved in 1 mL N,N-dimethylformamide 
(DMF). Potassium iodide (2.2 mg, 13.2 µmol), 
iodine (3.2 mg, 12.6 µmol) and sodium acetate        
(1 mg, 12.2 µmol) were added to the solution of 
sulochrin. The reaction mixture was stirred for       
17 hours (over-night) at room temperature. Then 
ethyl acetate was added into the reaction mixture, 
and the resulting mixture was washed with 5% 
sodium hydrogen sulphite. The organic layer was 
dried with Na2SO4. The resulting product was        
purified by silica gel TLC developed with 
CHCl3/MeOH (96 : 4). The final product was 
analyzed using LC-MS (Liquid Chromatography-
Mass Spectrometry). 
 
 
Synthesis of sulochrin-125I 
 
Na
125
I (2 µL, 1.5 mCi) was added into 
sulochrin-I solution (150 µL, 50µgram). The 
reaction mixture was stirred for 17 hours (over 
night) at room temperature and then purified by 
silica TLC developed with CHCl3/MeOH (95 : 5).  
 
 
Assay protocol with RBA method 
 
A 50 µL of phosphate buffer saline containing 
5% of bovine serum albumin and 2.5 µg                 
α-glucosidase was added into Total Binding (TB) 
and Non Spesific Binding (NSB) tubes. A 50 µL 
unlabeled sulochrin-I was added in the NSB tube 
and 50 µL of phosphate buffer saline was added into 
TB tube. Varying concentration of sulochrin-
125
I 
was diluted in phosphate buffer saline, then a 50 µL 
of this solution was added to each tube. The tubes  
were incubated for 2 hour at 37 
o
C (1
st
 incubation). 
Separation of the Receptor-Ligand Complex (L*R) 
from unbound ligand was done by adding solution 
of 10% polyethylene glycol in phosphate buffer 
saline to the tubes. The tubes were incubated for 30 
minute at 37 
o
C (2
nd
 incubation). After incubation, 
the tubes were decanted and counted using gamma 
counter. Results from this experiment were                
used to calculate value of Kd and maximum                     
binding (Bmax).  
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RESULTS AND DISCUSSION 
 
Synthesis of sulochrin-I 
 
Synthesis of sulochrin labeled by non 
radioactive iodine (sulochrin-I) was carried out 
prior to synthesis of sulochrin radioactive 
iodine (sulochrin-
125
I) by reacting sulochrin 
with iodine and potassium iodide at room 
temperature (Fig. 1). Extraction method was used 
to get sulochrin-I with addition of ethyl acetate and 
sodium hydrogen sulphite solution for binding the  
iodide excess. The sulochrin-I as the product will be 
in ethyl acetate phase. Purification of sulochrin-I 
was done by thin layer chromatography (TLC) 
method whereas using  silica 60F254 as stationary 
phase and mixture of chloroform:methanol (96:4) as 
mobile phase. The Rf of sulochrin and sulochrin-I 
were  0.5 and 0.7 respectively. This result showed 
that TLC method can be used as purification of 
sulochrin-I. 
 
O
OH
OH
H3C
H3CO
OH
COOCH3
I2, KI, NaOAc, DMF
stirrer overnight,rt
O
OH
OH
H3C
H3CO
OH
COOCH3
I
sulochrin sulochrin-I
 
Fig. 1. Reaction of sulochrin-I. 
 
Purified sulochrin-I was characterized by LC-
MS. The results showed that the synthesized product 
had molecular weight 458.9940 (M+H)
+
 (Fig. 2). 
We  predict  that   this   compound   has   molecular 
 
 
 
 
formula C17H15O7I.  This result showed that iodine 
was bound to the sulochrin molecule. This 
compound will be used to synthesis the sulochrin 
labeled radioactive iodine (sulochrin-
125
I). 
 
 
Synthesis of sulochrin-125I 
 
Prior to synthesis of sulochrin labeled 
radioactive iodine (sulochrin-
125
I), a 
radiochromatogram of Na
125
I was prepared using 
TLC method and showed in Fig. 3. Whatman paper 
No. 1 was used as stationary phase and 75% 
methanol solution as mobile phase. The 
radiochromatogram of Na
125
I showed the 
radiochemical purity at more than 99% which 
qualify for labeling process [16].  
 
 
 
Fig. 3. Radiochromatogram of Na125I using TLC method, 
whatman paper No.1 as stationary phase and 75% methanol 
solution as mobile phase. 
 
 
 
Fig. 2. The Mass Spectrum of sulochrin-I from synthesized product had molecular weight 458.9940 (M+H)+.  
0
500000
1000000
1500000
2000000
2500000
3000000
-2 3 8 13
ra
d
io
a
c
ti
v
it
y
 (
c
o
u
n
ts
 p
e
r 
m
in
u
te
) 
position (cm) 
MS positif 
20130403_Sulochrin_l 1221 (4.537) Cm (1205:1234-(1256:1362+1071:1186)) 
UCA214 
458.9940 100 
12:00:37 
05-Apr-2013 
1:TOF MS ES+ 
9.67e3 
441.7092 445.4761 447.0151 449.5924 452.9153 
453.0135 
455.0068 458.7714 
458.9587 
459.9961 
463.3928 
464.9040 
465.9067 
466.7596 468.6286 
m/z 0 
442 444 446 448 450 452 454 458 456 460 462 464 466 468 470 440 
24 
W. Lestari 
 
et al. / Atom Indonesia Vol. 40 No. 1 (2014) 22 - 26 
 
In this study, sulochrin-
125
I was used as tracer 
to study binding affinity of sulochrin as                             
α-glucosidase inhibitor using Radioligand Binding 
Assay (RBA) method. The method which was used 
for synthesis of sulochrin-
125
I was isotope exchange 
reaction, in which the non radioactive iodide was 
interchanged with radioactive iodide-
125
I. Sulochrin-
I was reacted with Na
125
I and stirred overnight at 
room temperature. TLC was used as purification 
method, using silica as stationary phase and mixture 
of chloroform : methanol (95:5) as mobile phase. 
Radiochromatogram of sulochrin-
125
I synthesis in 
Fig. 4 showed that retention time of sulochrin-
125
I 
and Na
125
I was different. Retention time of 
sulochrin-
125
I and 
125
I unreacted were 0.6 and 0 
respectively. This result showed that sulochrin-
125
I 
separated from unreacted Na
125
I. 
 
 
 
 
 
Fig. 4. Radiochromatogram of (A) Na125I, (B) sulochrin-125I 
before purification and (C) after purification using TLC method, 
silica 60F254 as stationary phase and mixture of 
chloroform:methanol (95:5) as mobile phase. 
 
 
Purified sulochrin-
125
I was then used to observe its 
binding affinity with α-glucosidase receptors using 
Radioligand Binding Assay (RBA) method. The 
RBA method was done to obtained value of 
dissociation constant (Kd) and maximun binding 
(Bmax). The data from assay protocol was 
radioactivity of NSB (Non Spesific Binding),       
TB (Total Binding) and TRA (Total Added).                  
The data was converted to concentration of NSB,        
TB and TRA, then Rosenthal curve was made to get 
the value of Kd and Bmax. As shown in Fig. 5,     
the curve gave equation y = -0.038x + 9.302        
with linearity ( r ) 0.871. The low value of this 
linearity of curve ( r ) is might be due to less optimal 
separation of bound radioligand from free 
radioligand. The separation is crucial step in RBA 
method, it is important to prevent dissociation of the 
receptor-radioligand complex which this parameter 
is measured [17]. The value of Kd and Bmax was 
obtained from this equation i.e Kd = -(1/slope) = -
(1/-0.038) = 26.316 nM and Bmax = intercept = 
9.302 nM. The Kd is equal to the concentration of 
ligand that will occupy 50% receptors [18], and it is 
mean that the concentration of sulochrin-
125
I needed 
to occupy 1.25 µg receptors is 26.316 nM. 
 
 
Fig. 5. Rosenthal curve for obtaining Kd and Bmax value. 
 
 
CONCLUSION 
 
Sulochrin showed its potency as an α-
glucosidase inhibitor. Sulochrin binding with α-
glucosidase enzyme as α-glucosidase inhibitor was 
studied using Radioligand Binding Assay (RBA) 
method. Assay sulochrin with RBA method needed 
sulochrin-
125
I as a tracer. Prior synthesis of 
sulochrin-
125
I, the procedure was firstly synthesizing 
the sulochrin-I. Synthesis of sulochrin-I and 
sulochrin-
125
I has been carried out. Sulochrin-I had 
molecular weight 457.9940 with molecular formula 
C17H15O7I. Sulochrin-
125
I was synthesized from 
sulochrin-I using isotope exchange method. Kd and 
Bmax value of sulochrin were 26.316 nM and   
9.302 nM respectively. This low Kd indicated that 
sulochrin was can bind to α-glucosidase. 
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